Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 4
2016 5
2017 2
2018 3
2019 5
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Phase variation in Mycobacterium tuberculosis glpK produces transiently heritable drug tolerance.
Safi H, Gopal P, Lingaraju S, Ma S, Levine C, Dartois V, Yee M, Li L, Blanc L, Ho Liang HP, Husain S, Hoque M, Soteropoulos P, Rustad T, Sherman DR, Dick T, Alland D. Safi H, et al. Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19665-19674. doi: 10.1073/pnas.1907631116. Epub 2019 Sep 5. Proc Natl Acad Sci U S A. 2019. PMID: 31488707 Free PMC article.
Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.
Chen C, Gardete S, Jansen RS, Shetty A, Dick T, Rhee KY, Dartois V. Chen C, et al. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02107-17. doi: 10.1128/AAC.02107-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29463541 Free PMC article.
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, Eum S, Shim T, Barry CE 3rd, Zimmerman M, Dartois V, Savic RM. Strydom N, et al. PLoS Med. 2019 Apr 2;16(4):e1002773. doi: 10.1371/journal.pmed.1002773. eCollection 2019 Apr. PLoS Med. 2019. PMID: 30939136 Free PMC article.
Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.
Gopal P, GrĂ¼ber G, Dartois V, Dick T. Gopal P, et al. Trends Pharmacol Sci. 2019 Dec;40(12):930-940. doi: 10.1016/j.tips.2019.10.005. Epub 2019 Nov 6. Trends Pharmacol Sci. 2019. PMID: 31704175 Free article. Review.
Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.
Sarathy JP, Via LE, Weiner D, Blanc L, Boshoff H, Eugenin EA, Barry CE 3rd, Dartois VA. Sarathy JP, et al. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e02266-17. doi: 10.1128/AAC.02266-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29203492 Free PMC article.
Targeted protein degradation in antibacterial drug discovery?
Gopal P, Dick T. Gopal P, et al. Prog Biophys Mol Biol. 2020 May;152:10-14. doi: 10.1016/j.pbiomolbio.2019.11.005. Epub 2019 Nov 16. Prog Biophys Mol Biol. 2020. PMID: 31738980 Free article. Review.
Impact of immunopathology on the antituberculous activity of pyrazinamide.
Blanc L, Sarathy JP, Alvarez Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Sacchettini J, Savic RM, Gengenbacher M, Podell BK, Prideaux B, Ioerger T, Dick T, Dartois V. Blanc L, et al. J Exp Med. 2018 Aug 6;215(8):1975-1986. doi: 10.1084/jem.20180518. Epub 2018 Jul 17. J Exp Med. 2018. PMID: 30018074 Free PMC article.
The Risk of Treating Populations Instead of Patients.
Deitchman AN. Deitchman AN. CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):256-258. doi: 10.1002/psp4.12402. Epub 2019 Apr 2. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 30884214 Free PMC article. No abstract available.
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses.
Lenaerts A, Barry CE 3rd, Dartois V. Lenaerts A, et al. Immunol Rev. 2015 Mar;264(1):288-307. doi: 10.1111/imr.12252. Immunol Rev. 2015. PMID: 25703567 Free PMC article. Review.
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.
Dartois V. Dartois V. Nat Rev Microbiol. 2014 Mar;12(3):159-67. doi: 10.1038/nrmicro3200. Epub 2014 Feb 3. Nat Rev Microbiol. 2014. PMID: 24487820 Free PMC article. Review.
22 results
Jump to page
Feedback